Karyopharm Therapeutics Inc. (KPTI) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Other equities analysts have also issued research reports about the company. Jefferies Group LLC reaffirmed a buy rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, July 14th. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the company a buy rating in a research note on Saturday, June 24th. Robert W. Baird reaffirmed an outperform rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, April 6th. Wedbush reaffirmed an outperform rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, April 5th. Finally, ValuEngine downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a report on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $14.46.

Shares of Karyopharm Therapeutics (NASDAQ KPTI) opened at 9.25 on Tuesday. The stock’s market cap is $435.84 million. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63. The firm has a 50-day moving average price of $9.23 and a 200-day moving average price of $10.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, May 4th. The company reported ($0.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.04. Karyopharm Therapeutics had a negative net margin of 50,646.40% and a negative return on equity of 72.41%. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.02 million. During the same period last year, the company earned ($0.75) EPS. Equities analysts forecast that Karyopharm Therapeutics will post ($2.68) EPS for the current year.

TRADEMARK VIOLATION WARNING: “[[title]]” was published by [[site]] and is the sole property of of [[site]]. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at [[permalink]].

Large investors have recently bought and sold shares of the stock. Teza Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the first quarter valued at about $169,000. Metropolitan Life Insurance Co. NY increased its stake in Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares in the last quarter. American International Group Inc. increased its stake in Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after buying an additional 2,836 shares in the last quarter. C WorldWide Group Holding A S increased its stake in Karyopharm Therapeutics by 30.2% in the first quarter. C WorldWide Group Holding A S now owns 16,928 shares of the company’s stock valued at $217,000 after buying an additional 3,928 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at $343,000. Hedge funds and other institutional investors own 57.09% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com